Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia
Abstract
There may be subtypes in treatment-resistant schizophrenia (TRS), and one of the subtypes may be related to dopamine supersensitivity psychosis (DSP). In developing strategies for prevention and treatment TRS, it is important to clarify the role of DSP in TRS. TRS patients were recruited from 3 hospitals for the present study. Through chart reviews, all patients were judged as either TRS or not, and then possible TRS patients were investigated about their past/present histories of DSP episode(s) by direct interviews. We then compared each factor between the groups with and without DSP episode(s). Out of 611 patients screened, 147 patients met the criteria for TRS and were included in the present analysis. These were divided into groups with and without DSP, comprising 106 (72.1%) and 41 patients (27.9%), respectively. Clinical characteristics in the two groups were similar, except for drug-induced movement disorders (DIMDs), which were significantly more important in DSP patients. Of the DSP patients, 42% and 56% experienced rebound psychosis and tolerance to antipsychotic effects, respectively. The present study revealed that approximately 70% of TRS patients experienced one or more DSP episodes, which may have a strong impact on the long-term prognosis of patients with schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These effects, together with a risk of abuse and misuse, made ketamine a popular street drug.
“These effects, together with a risk of abuse and misuse, made ketamine a popular street drug, also known as 'Special K' [141].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [141]
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,706 · see citing works
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350 · see citing works
Scale for the Assessment of Negative Symptoms
Andreasen, N. C. (1982) · PsycTESTS Dataset · doi:10.1037/t12696-000 · Cited by 1,878 · see citing works
The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations
Andreasen, N. C. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291496 · Cited by 1,532 · see citing works
Deficit and nondeficit forms of schizophrenia: the concept
Carpenter, W. T., Heinrichs, D. W., & Wagman, A. M. I. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,329 · see citing works
The schedule for the deficit syndrome: An instrument for research in schizophrenia
Kirkpatrick, B. R., Buchanan, R. W., McKenny, P. D., Alphs, L. D., & Carpenter, W. T. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90153-4 · Cited by 802 · see citing works
Chakos, M., Lieberman, J. A., Hoffman, E. B., Bradford, D. W., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 632 · see citing works
Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective
Lieberman, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00147-x · Cited by 486 · see citing works
Time Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia
Lieberman, J. A. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170047006 · Cited by 446 · see citing works
Dopamine supersensitivity correlates with D2 High states, implying many paths to psychosis
Seeman, P. M., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., Premont, R. T., Sotnikova, T. D., Boksa, P., El-Ghundi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409766102 · Cited by 353 · see citing works
Psychosis pathways converge via D2High dopamine receptors
Seeman, P. M., Schwarz, J., Chen, J., Szechtman, H., Perreault, M. L., McKnight, G. S., Roder, J., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 328 · see citing works
Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia
Fenton, W. S., & McGlashan, T. H. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.351 · Cited by 260 · see citing works
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242 · see citing works
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231 · see citing works
Neuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224 · see citing works
Periods of Recovery in Deficit Syndrome Schizophrenia: A 20-Year Multi-follow-up Longitudinal Study
Strauss, G. P., Harrow, M., Grossman, L. S., & Rosen, C. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn167 · Cited by 206 · see citing works
Withdrawal syndromes associated with antipsychotic drugs
Gárdos, G., Jo, C., & Tarsy, D. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1321 · Cited by 192 · see citing works
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · see citing works
Masand, P. S., Roca, M., Turner, M. S., & Kane, J. M. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08r00612 · Cited by 151 · see citing works
Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change
Chong, M., Tan, C. H., Fujii, S., Yang, S., UNGVARI, G. S., Si, T., Chung, E. K., Sim, K., Tsang, H., & Shinfuku, N. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01194.x · Cited by 146 · see citing works
Sim, K., Su, A., Fujii, S., Yang, S., Chong, M., Ungvari, G. S., Si, T., Chung, E. K., Tsang, H., Chan, Y. H., et al. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02102.x · Cited by 142 · see citing works
Severe cases of neuroleptic-induced supersensitivity psychosis
Chouinard, G. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90050-2 · Cited by 123 · see citing works
Remission in Schizophrenia: Critical and Systematic Review
AlAqeel, B., & Margolese, H. C. (2012) · Harvard Review of Psychiatry · doi:10.3109/10673229.2012.747804 · Cited by 113 · see citing works
A five-year followup study of deficit and nondeficit schizophrenia
Tek, C., Kirkpatrick, B. W., & Buchanan, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00146-8 · Cited by 111 · see citing works
Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A. A. E., Øhlenschlæger, J., le Quach, P., Christensen, T. Ø., Krarup, G., Jørgensen, P., & Nordentoft, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.018 · Cited by 106 · see citing works
Chouinard, G., Annable, L., Ross‐Chouinard, A., & Mercier, P. (1988) · PubMed · Cited by 102 · see citing works
Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., & Hashimoto, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828ea95c · Cited by 98 · see citing works
Self-citationTadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr006 · Cited by 92 · see citing works
Self-citationApathy in first episode psychosis patients: A ten year longitudinal follow-up study
Evensen, J. H., Røssberg, J. I., Barder, H. E., Haahr, U., Hegelstad, W. T. V., Joa, I., Johannessen, J. O., Larsen, T. K., Melle, I. S., Opjordsmoen, S., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.12.019 · Cited by 86 · see citing works
Is schizophrenia a dopamine supersensitivity psychotic reaction?
Seeman, M. V., & Seeman, P. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.003 · Cited by 82 · see citing works
A 5-Year Prospective Longitudinal Study of Tardive Dyskinesia
Chouinard, G., Annable, L., Ross‐Chouinard, A., & Mercier, P. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808001-00005 · Cited by 58 · see citing works
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55 · see citing works
Self-citationThe psychiatric symptomatology of deficit schizophrenia: A meta-analysis
Cohen, A. S., Brown, L. A., & Minor, K. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.10.010 · Cited by 45 · see citing works
Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study
Neto, J. H., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300007 · Cited by 42 · see citing works
Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose
Owen, R. R. (2000) · International Journal for Quality in Health Care · doi:10.1093/intqhc/12.6.475 · Cited by 37 · see citing works
Antipsychotic Dosage at Hospital Discharge and Outcomes Among Persons With Schizophrenia
Sohler, N., Walkup, J. T., McAlpine, D. D., Boyer, C. A., & Olfson, M. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.9.1258 · Cited by 33 · see citing works
[The Japanese version of the Calgary Depression Scale for Schizophrenics (JCDSS)].
Kaneda, Y., Ohmori, T., & Addington, D. E. (2000) · PubMed · Cited by 15 · see citing works
Kimura, H., Kanahara, N., Watanabe, H., & Iyo, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.008 · Cited by 14 · see citing works
Self-citationJuarez-Reyes, M., Shumway, M., Battle, C. L., Bacchetti, P., Hansen, M. S., & Hargreaves, W. A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(96)00130-3 · Cited by 11 · see citing works
Inada, T. (1996) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359 · see citing works
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244 · see citing works
Iasevoli, F., Giordano, S., Balletta, R., Latte, G., Formato, M. V., Prinzivalli, E., Berardis, D. D., Tomasetti, C., & de Bartolomeis, A. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.08.010 · Cited by 178 · see citing works
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
Yin, J., Barr, A. M., Ramos‐Miguel, A., & Procyshyn, R. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160606093602 · Cited by 97 · see citing works
Oda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 71 · see citing works
Self-citationBrain, C., Kymes, S. M., DiBenedetti, D. B., Brevig, T., & Velligan, D. I. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1833-5 · Cited by 70 · see citing works
Harrow, M., Jobe, T. H., Faull, R. N., & Yang, J. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.06.069 · Cited by 67 · see citing works
Clozapine discontinuation withdrawal symptoms in schizophrenia
Blackman, G., & Oloyede, E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032053 · Cited by 54 · see citing works
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53 · see citing works
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 53 · see citing works
Self-citationAntipsychotic-evoked dopamine supersensitivity
Servonnet, A., & Samaha, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.007 · Cited by 46 · see citing works
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Amato, D., Kruyer, A., Samaha, A., & Heinz, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00314 · Cited by 46 · see citing works
Treatment-resistant schizophrenia: How far have we traveled?
Pandey, A., & Kalita, K. N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.994425 · Cited by 45 · see citing works
Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity
Kruyer, A., Parrilla-Carrero, J., Powell, C., Brandt, L., Gutwinski, S., Angelis, A., Chalhoub, R., Jhou, T. C., Kalivas, P. W., & Amato, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01235-6 · Cited by 36 · see citing works
Emsley, R. A., Nuamah, I. F., Gopal, S., Hough, D. W., & Fleischhacker, W. W. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11874 · Cited by 34 · see citing works
5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity
Charron, A., Hage, C. E., Servonnet, A., & Samaha, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.10.002 · Cited by 33 · see citing works
Schrader, J. M., Irving, C. M., Octeau, J. C., Christian, J. A., Aballo, T. J., Kareemo, D. J., Conti, J., Camberg, J. L., Lane, J. R., Javitch, J. A., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004682 · Cited by 31 · see citing works
Mentzel, T. Q., Lieverse, R., Bloemen, O., Viechtbauer, W., van Harten, P. N., & The Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000666 · Cited by 30 · see citing works
Yamanaka, H., Kanahara, N., Suzuki, T., Takase, M., Moriyama, T., Watanabe, H., Hirata, T., Asano, M., & Iyo, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.013 · Cited by 29 · see citing works
Self-citationChestnykh, D., Amato, D., Kornhuber, J., & Müller, C. P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113144 · Cited by 29 · see citing works
Kimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26 · see citing works
Self-citationYing, J., Chew, Q. H., McIntyre, R. S., & Sim, K. (2023) · Genes · doi:10.3390/genes14030689 · Cited by 26 · see citing works
Long‐term antipsychotic treatment of schizophrenia: does it help or hurt over a 20‐year period?
Harrow, M., & Jobe, T. H. (2018) · World Psychiatry · doi:10.1002/wps.20518 · Cited by 25 · see citing works
Overview of schizophrenia research and treatment in Pakistan
Nawaz, R., Gul, S., Amin, R., Huma, T., & Mughairbi, F. A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05545 · Cited by 23 · see citing works
Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia
Nakata, Y., Kanahara, N., Kimura, H., Watanabe, H., & Iyo, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000160 · Cited by 23 · see citing works
Self-citationIasevoli, F., Avagliano, C., D'Ambrosio, L., Barone, A., Ciccarelli, M., Simone, G. D., Mazza, B., Vellucci, L., & de Bartolomeis, A. (2023) · Biomedicines · doi:10.3390/biomedicines11030895 · Cited by 25 · see citing works
Patrón de uso de clozapina en España. Variabilidad e infraprescripción
Sanz-Fuentenebro, F. J., Uriarte, J. J. U., Dalmau, P. B., Molina, V., & Bernardo, M. (2018) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.02.005 · Cited by 20 · see citing works
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18309 · Cited by 19 · see citing works
Servonnet, A., Minogianis, E.-A., Bouchard, C., Bedard, A., Lévesque, D., Rompré, P., & Samaha, A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.015 · Cited by 19 · see citing works
Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
Correll, C. U., Brevig, T., & Brain, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s234813 · Cited by 17 · see citing works
Tachibana, M., Niitsu, T., Watanabe, M., Hashimoto, T., Kanahara, N., Ishikawa, M., & Iyo, M. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.014 · Cited by 17 · see citing works
Self-citationBalcıoğlu, Y. H., Gökçay, H., & Yeşilkaya, Ü. H. (2020) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000404 · Cited by 15 · see citing works
Kanahara, N., Kimura, H., Oda, Y., Ito, F., & Iyo, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210125152815 · Cited by 14 · see citing works
Self-citationNiitsu, T., Hata, T., Nishimoto, M., Hosoda, Y., Kimura, A., Oda, Y., Suzuki, M., Takase, N., Seki, R., Fujita, K., et al. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102369 · Cited by 14 · see citing works
Self-citationKimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 14 · see citing works
Self-citationUnique effect of clozapine on adenosine A2A-dopamine D2 receptor heteromerization
Valle-León, M., Casajuana-Martín, N., del Torrent, C. L., Argerich, J., Gómez-Acero, L., Sahlholm, K., Ferré, S., Pardo, L., & Ciruela, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114327 · Cited by 14 · see citing works
Iasevoli, F., Avagliano, C., Altavilla, B., Barone, A., Ciccarelli, M., D’Ambrosio, L., Francesco, D. N., Razzino, E., Fornaro, M., & de Bartolomeis, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.109 · Cited by 14 · see citing works
Continuous versus extended antipsychotic dosing in schizophrenia: Less is more
Servonnet, A., Uchida, H., & Samaha, A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113076 · Cited by 13 · see citing works
Moreno-Sancho, L., Juncal‐Ruíz, M., Vázquez-Bourgón, J., de la Foz, V. O., Son, J. M.-V., Tordesillas‐Gutiérrez, D., Setién‐Suero, E., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.07.015 · Cited by 12 · see citing works
Kanahara, N., Takase, M., Sasaki, T. G., Honma, M., Fujita, Y., Tadokoro, S., Suzuki, H., Yamanaka, H., Noda, S., Yanahashi, S., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000322 · Cited by 12 · see citing works
Self-citationOda, Y., Fujita, Y., Oishi, K., Nakata, Y., Takase, M., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4695-5 · Cited by 11 · see citing works
Self-citationKanahara, N., Yamanaka, H., Suzuki, T., Takase, M., & Iyo, M. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1853-1 · Cited by 11 · see citing works
Self-citationKanahara, N., Oda, Y., Kimura, H., Watanabe, H., Hashimoto, K., & Iyo, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s86042 · Cited by 11 · see citing works
Self-citationEffects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats
Kimura, M., Oda, Y., Oishi, K., Yoshino, K., Kimura, H., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.062 · Cited by 9 · see citing works
Self-citationKimura, M., Oda, Y., Hirose, Y., Kimura, H., Yoshino, K., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173288 · Cited by 8 · see citing works
Self-citationOishi, K., Kanahara, N., Takase, M., Oda, Y., Nakata, Y., Niitsu, T., Ishikawa, M., Sato, Y., & Iyo, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207133 · Cited by 8 · see citing works
Self-citationTakao, N., Murai, T., & Fujiwara, H. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242495 · Cited by 8 · see citing works
Kanahara, N., Yamanaka, H., Shiko, Y., Kawasaki, Y., & Iyo, M. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111422 · Cited by 7 · see citing works
Self-citationStanovaya, V. V., Guseynova, Z. T., Ivanov, M. V., & Bigday, E. V. (2023) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2023-893 · Cited by 6 · see citing works
Skouras, S., Kleinert, M.-L., Lee, E. H. M., Hui, C. L. M., Suen, Y. N., Camchong, J., Chong, C. S. Y., Chang, W. C., Chan, S. K. W., Lo, W. T.-L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae094 · Cited by 6 · see citing works
Detanac, M., Williams, C., Dragović, M., Shymko, G., & John, A. P. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241274314 · Cited by 6 · see citing works
Masumo, Y., Kanahara, N., Kogure, M., Yamasaki, F., Nakata, Y., & Iyo, M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000442 · Cited by 5 · see citing works
Self-citationYamasaki, F., Kanahara, N., Nakata, Y., Koyoshi, S., Yanagisawa, Y., Saito, T., Oiwa, T., Kogure, M., Sasaki, T. G., Yoshida, T., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231177268 · Cited by 5 · see citing works
Self-citationTakase, M., Kimura, H., Kanahara, N., Nakata, Y., & Iyo, M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119900982 · Cited by 5 · see citing works
Self-citationMa, C.-H., Chan, H., Hsieh, M. H., Liu, C., Liu, C., Hwu, H., Kuo, C., Chen, W. J., & Hwang, T. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211064396 · Cited by 4 · see citing works
Risk factors for early-phase clozapine discontinuation: A nested case-control study
Tsukiji, M., Sasaki, T. G., Nakata, Y., Ota, K., Aoki, T., Hara, K., Mamada, T., Nakane, J., Kogure, M., Seki, R., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102745 · Cited by 4 · see citing works
Self-citationKobayashi, R., Oda, Y., Hayatsu, R., Ohki, N., Akutsu, M., Oiwa, T., Komatsu, H., Niitsu, T., Sasaki, T. G., & Iyo, M. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20929561 · Cited by 4 · see citing works
Self-citationKimura, M., Oda, Y., Kimura, H., Nangaku, M., Hirose, Y., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173114 · Cited by 3 · see citing works
Self-citationConsenso argentino sobre diagnóstico y tratamiento de la esquizofrenia resistente al tratamiento
Corral, R. M. (2021) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v32i154.119 · Cited by 3 · see citing works
Kogure, M., Kanahara, N., Kimura, M., Hanaoka, S., Hirano, H., & Iyo, M. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001564 · Cited by 2 · see citing works
Self-citationNeurological Disorders: Biochemistry of Drug Resistance and Future Challenges
Ahmad, M. S., Batool, S., Islam, A., Jabeen, A., Noureen, A., SHAMSHAD, S., Zainab, T., Shahid, M., & Ahmed, W. (2021) · Springer eBooks · doi:10.1007/978-3-030-76320-6_9 · Cited by 2 · see citing works
Dopamine Receptor Supersensitivity and Schizophrenia
Peeters, L. D., & Brown, R. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_224-1 · Cited by 2 · see citing works
TAKANO, S., Hashimoto, T., Hayatsu, R., Kanahara, N., & Nakazato, M. (2025) · Cureus · doi:10.7759/cureus.93361 · Cited by 1 · see citing works
Self-citationTreatment-resistant schizophrenia: pathophysiology and the role of neuroimaging and therapeutics
Petch, J., Martinez‐Gonzalez, B., & Shergill, S. S. (2026) · BJPsych Advances · doi:10.1192/bja.2025.10195 · Cited by 1 · see citing works
Krzystanek, M., Bieś, R., & Bąk‐Sosnowska, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093745 · Cited by 1 · see citing works
Okada, K., Kanahara, N., Otsuka, Y., Kobayashi, R., Yamanaka, H., Takaoki, Y., Ito, F., Komatsu, H., Yoshida, T., Kikuchi, Y., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.05.019 · Cited by 1 · see citing works
Self-citationDopamine Receptor Supersensitivity and Schizophrenia
Peeters, L. D., & Brown, R. W. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_224 · Cited by 1 · see citing works
Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_5
Sharon, M., & Mewada, A. (2018) · doi:10.1002/9781119460435.refs
Pattern of use of clozapine in Spain. Variability and under-prescription
Sanz-Fuentenebro, F. J., Uriarte, J. J. U., Dalmau, P. B., Molina, V., & Arroyo, M. B. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.012
Breakthrough Psychosis and Long-Acting Injectable Antipsychotics
Joo, E.-J., Lee, K. Y., Jeong, S. H., & Kim, Y. S. (2023) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2023.26.1.1
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00003-9
Parikh, P., Wubuli, D., Dadem, A. R., Gultekin, I., Chandra-Kaushik, A., Wang, E., Narravula, R., Chandra, A., Buddhavarapu, I., & Mendelowitz, A. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253283
Biological aspects of drug resistance in schizophrenia
Tikhonov, D. V., & Kaleda, V. G. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612601119
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v1
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v2
Richter, S., & Carol, S. B. (2026) · Research Square · doi:10.21203/rs.3.rs-8935281/v3
Exploring Combination Therapy for the Management of Psychotic Disorders: A Comprehensive Review
Sharma, S., Behl, D. S., Suri, P., Sharma, T., Rai, G., Gauba, P., & Dang, S. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128440388260522052532
Dopamine supersensitivity psychosis: a critical evaluation of diagnostic validators
Hudnik, L. K., Kosmačin, I., Pjevac, M., Dolžan, V., & Bon, J. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03207-y
- Authors
- Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M.
- Affiliations
- Chiba University (JP)
- Corresponding author
- Kanahara, Nobuhisa
- ORCID
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 227
- Issue
- 2-3
- Pages
- 278-282
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W2001661616
- Cited by
- 81
- References
- 43
- Citations by year
- 2026: 9 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 15 · 2020: 10 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 5 · 2015: 4
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- SENSHIN Medical Research Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- treatment-resistant schizophrenia, drug-induced movement disorders, schizophrenia subtypes, prognosis
- MeSH terms
- Adult, Dopamine, Drug Tolerance, Female, Humans, Male, Middle Aged, Movement Disorders, Psychoses, Substance-Induced, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
